Technology
Health
Pharmaceutical

BioDelivery

$5.10
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (3.24%) Today
+$0.16 (3.24%) Today

Why Robinhood?

You can buy or sell BioDelivery and other stocks, options, ETFs, and crypto commission-free!

About

BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. It focuses on pharmaceutical products in the areas of pain management and addiction. Read More The company was founded in 1997 and is headquartered in Raleigh, NC.

Employees
164
Headquarters
Raleigh, North Carolina
Founded
1997
Market Cap
349.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
560.73K
High Today
$5.10
Low Today
$4.95
Open Price
$4.97
Volume
280.90K
52 Week High
$5.21
52 Week Low
$1.70

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
US
North America

News

Yahoo FinanceMar 15

BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

BioDelivery Sciences International, Inc. BDSI reported loss of 10 cents per share for fourth-quarter 2018, meeting the Zacks Consensus Estimate. In the year-ago quarter, the company had recorded a loss of 29 cents per share. Revenues were $18 million in the reported quarter, up 44.1% from the year-ago period and 27.4% sequentially. The increase in sales was mainly driven by strong demand for Belbuca, which exceeded the company’s expectations. The top line beat the Zacks Consensus Estimate of $16.15 million...

441
Seeking AlphaMar 15

BioDelivery Sciences International, Inc.'s (BDSI) CEO Herm Cukier on Q4 2018 Results - Earnings Call Transcript

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q4 2018 Earnings Conference Call March 14, 2019 4:30 PM ET Company Participants Herm Cukier - Chief Executive Officer Scott Plesha - President and Chief Commercial Officer Thomas Smith - Chief Medical Officer Terry Coelho - Chief Financial Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Esther Hong - Janney Capital Markets Tim Lugo - William Blair Matt Kaplan - Ladendburg Thalmann Oren Livnat - HC Wainwright Operator ...

271
Seeking AlphaMar 12

BioDelivery Sciences - Investment In Ending The Opioid Epidemic

Buprenorphine is finally getting the recognition by doctors and insurance companies for being a safer long-term pain treatment alternative.

278

Earnings

-$0.29
-$0.23
-$0.16
-$0.10
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.10 per share
Actual
-$0.10 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.